Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
Mo | DAXOR CORP - 8-K, Current Report | 1 | SEC Filings | ||
Mo | Daxor acquires Volumex and Megatope from existing supplier | 1 | Seeking Alpha | ||
Mo | Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics | 93 | GlobeNewswire (Europe) | Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology... ► Artikel lesen | |
22.03. | Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 | 1 | GlobeNewswire (USA) | ||
18.03. | Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 | 20 | GlobeNewswire (Europe) | Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in... ► Artikel lesen | |
18.03. | Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders | 31 | GlobeNewswire (Europe) | Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders... ► Artikel lesen | |
11.03. | Daxor Corporation: Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base | 2 | GlobeNewswire (USA) | ||
08.03. | Daxor Corporation: Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients | 2 | GlobeNewswire (USA) | ||
26.02. | Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference | 1 | GlobeNewswire (USA) | ||
12.02. | Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions | 181 | GlobeNewswire (Europe) | Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions... ► Artikel lesen | |
02.01. | DAXOR CORP - 8-K, Current Report | - | SEC Filings | ||
02.01. | Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer | 228 | GlobeNewswire (Europe) | The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader... ► Artikel lesen | |
28.11.23 | DAXOR CORP - 8-K, Current Report | - | SEC Filings | ||
13.11.23 | Daxor Corporation: New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients | 238 | GlobeNewswire (Europe) | Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood... ► Artikel lesen | |
27.10.23 | DAXOR CORP - 8-K, Current Report | 1 | SEC Filings | ||
13.10.23 | Daxor Corporation: Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting | 1 | GlobeNewswire (USA) | ||
11.10.23 | Daxor Corporation: New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting | 1 | GlobeNewswire (USA) | ||
28.08.23 | Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders | 414 | GlobeNewswire (Europe) | Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to Shareholders... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SIEMENS HEALTHINEERS | 56,72 | +0,60 % | Kurs der Siemens Healthineers-Aktie verharrt auf Vortags-Niveau (55,06 €) | Wenig Kursbewegung zur Stunde bei der Siemens Healthineers-Aktie . Der jüngste Kurs betrug 55,06 Euro. Ein geringes Minus von 0,36 Prozent zeigt die Kurstafel für die Aktie von Siemens Healthineers... ► Artikel lesen | |
TELADOC HEALTH | 14,055 | +0,36 % | Here's Why Investors Should Hold Teladoc (TDOC) Stock Now | ||
THERMO FISHER | 540,00 | +0,33 % | Research and Markets: 2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report Featuring IQVIA, ICON, Parexel, Fortrea (formerly Labcorp), PPD/Thermo Fisher, and Syneos Health - ResearchAndMarkets.com | The "2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report" has been added to ResearchAndMarkets.com's offering.
The biopharmaceutical clinical development landscape... ► Artikel lesen | |
UNITEDHEALTH | 455,00 | -0,33 % | UnitedHealth's Cyberattack - Company Provides Aid Of Over $3B To Affected Providers | ||
BICO GROUP | 4,078 | +0,57 % | Schock-News für Bico Group Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
SERNOVA | 0,382 | +2,36 % | Sernova gibt Entwicklungen im Management bekannt | London, Ontario und Boston, Massachusetts, den 11. März 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FWB/XETRA: PSH), ein in der klinischen Phase befindliches Unternehmen, das sich auf
die... ► Artikel lesen | |
VITA 34 | 4,980 | +6,87 % | Biotech Report: Vita34 klettern kräftig, Evotec und Biontech leichter | (shareribs.com) Frankfurt / New York 15.03.2024 - Biotech-Aktien haben sich am Freitag überwiegend leichter präsentiert. Im deutschen Handel verloren unter anderem Evotec deutlich. Auch an der Wall... ► Artikel lesen | |
GERATHERM MEDICAL | 4,320 | -0,46 % | Geratherm Medical AG: Geratherm meldet Kurzarbeit an; Kursziel gesenkt; mwb research bekräftigt KAUFEN | Geratherm hat angekündigt, im Werk Geratal Kurzarbeit zu beantragen, weil der Absatz von Fieberthermometern aufgrund des milden Winters unter Plan lag. Der Anteil der Fieberthermometer am Gesamtumsatz... ► Artikel lesen | |
INNOVAQOR | - | - | InnovaQor, Inc. - 8-K, Current Report | ||
ALIGN TECHNOLOGY | 303,20 | -0,21 % | Here's Why You Should Buy Align Technology (ALGN) Stock Now | ||
ALCON | 76,96 | +0,10 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
DEXCOM | 129,08 | +0,36 % | DexCom Aktie: Insiderverkäufe und Marktbewertung | DexCom, ein Unternehmen im Bereich der medizinischen Geräte, spezialisiert auf kontinuierliche Glukoseüberwachungssysteme für Diabetiker, zeigt eine signifikante Aktivität auf Führungsebene. Ein leitender... ► Artikel lesen | |
HIMS & HERS HEALTH | 14,200 | -1,05 % | Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth... ► Artikel lesen | |
PLUS THERAPEUTICS | 1,676 | -0,48 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement... ► Artikel lesen | |
INMODE | 20,160 | +0,50 % | InMode LTD: InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M | YOKNEAM, Israel, Feb. 13, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results... ► Artikel lesen |